Ivermectin therapy for young children less than 2 years with scabies infection: a multicentre phase 2 non-randomised trial

Background: Ivermectin is effective for treating scabies but is unlicensed for children <15 kg. Our previous trial in children aged 2-4 years showed ivermectin was safe and effective, with a 3 mg dose achieving drug exposures comparable to the licensed dose in children weighing ≥15 kg. Using population pharmacokinetic modelling, an age-based dosing strategy for […]